Popular Articles

New Scientific Data On ADHD Treatments Presented By Shire At National Psychiatric Scientific Meeting
Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, has announced that it will present key scientific data on its Attention Deficit Hyperactivity Disorder (ADHD) treatments lisdexamfetamine dimesylate (CII) and investigational non-scheduled guanfacine extended release, at a national scientific meeting of psychiatrists being held May 16 -21 in San Francisco, CA.

New Software To Improve Clinical Trial Performance
TranSenda International, LLC announced today that it is developing a new solution, Cortex, designed to improve an organization"s ability to manage a clinical trial"s performance. Based upon patent-pending ClinBUS® data interchange technology already in use in TranSenda"s Office-Smart solutions, Cortex will enable organizations to leverage the power of access to centralized operational data from all applications used across all clinical studies. For years the industry has struggled with an increasingly fragmented environment of disconnected clinical applications, sites and partners. TranSenda"s Cortex, with its proven ClinBUS technology, represents a breakthrough in managing and controlling studies within a common environment-independent of study data formats and clinical trial applications.
News of the day
Next-Generation Pain-Reliever: Developing A Safer Form Of Acetaminophen
Scientists in Louisiana are reporting development of a process for producing large batches of a new and potentially safer form of acetaminophen, the widely used pain-reliever now the of growing concern over its potentially toxic effects on the liver. Their study, which could speed development of a next-generation pain-reliever, is scheduled for the July 17 issue of ACS" Organic Process Research & Development, a bi-monthly journal.
Oncology

Combination Of Interventions Could Reduce Childhood Pneumonia Deaths By 90%, Study Says

A combination of measures taken to improve nutrition, indoor air pollution, immunization and child pneumonia case management could reduce total child mortality worldwide by 17 percent and global pneumonia deaths by more than 90 percent, according to a study published in the June issue of the Bulletin of the World Health Organization, UPI reports. Researchers said that the "most cost-effective interventions were programs to promote better community-based treatment of pneumonia, promotion of exclusive breastfeeding, zinc supplementation and vaccination for Hib and S. pneumoniae," UPI reports. According to the study, the burning of solid fuels like wood for cooking and heating, contributed at least 20 percent to the burden of childhood pneumonia (UPI, 6/3). Louis Niessen, lead author of the study and an associate professor in the Bloomberg School"s Department of International Health, said, "The interventions we examined already exist, but are not fully implemented in the developing world. In addition, implementation of these interventions do not require a great deal of new infrastructure to carry out." If these interventions were fully funded and implemented, they "could bring us a big step closer towards reaching the U.N. Millennium Development Goals," Niessen said. Majid Ezzati, co-investigator of the study and associate professor at the Harvard School of Public Health, said that the next step is to examine "how donors and countries currently deliver these interventions and want to progress in the coming years" (Johns Hopkins Bloomberg School of Public Health release, 6/1). This information was reprinted from globalhealth.kff.org with kind permission from the Henry J. Kaiser Family Foundation. You can view the entire Kaiser Daily Global Health Policy Report, search the archives and sign up for email delivery at globalhealth.kff.org. © Henry J. Kaiser Family Foundation. All rights reserved.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):